Review of therapeutic applications of radiolabeled functional nanomaterials. Sci 20 , Sofou, S. Antibody-targeted liposomes in cancer therapy and imaging. Drug Deliv 5 , — Lee, E. Radioembolization for the treatment of primary and metastatic liver cancers. Imaging 53 , — Wu, A. Arming antibodies: prospects and challenges for immunoconjugates. Hu, S. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment single-chain Fv-C H 3 which exhibits rapid, high-level targeting of xenografts.
Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2 , 21—36 Cheung, N. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. Boerman, O. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.
Chang, C. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Cancer Ther. McBride, W.
Catz, B. Treatment of cancer of the thyroid postoperatively with suppressive thyroid medication, radioactive iodine, and thyroid-stimulating hormone. Cancer 12 , — Hamilton, J. Studies in iodine metabolism of the thyroid gland in situ by the use of radio-iodine in normal subjects and in patients with various types of goiter.
Benua, R. Relation of radioiodine dosimetry to results and complications in treatment of metastatic thyroid cancer. Radium Ther. Maxon, H. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. Livingood, J. Radioactive iodine isotopes. Knapp, R.
Radiopharmaceuticals for Therapy - Springer, Radioactive iodine as an indicator in thyroid physiology - Iodine collection by normal and hyperplastic thyroids in rabbits. Cooper, D. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
Thyroid 19 , — Fagin, J. Biologic and clinical perspectives on thyroid cancer. Gao, W. Internal radiotherapy using 32 P colloid or microsphere for refractory solid tumors. Morris, M. Radium mechanism of action: implications for use in treatment combinations. Leung, C. Dose-dependent growth delay of breast cancer xenografts in the bone marrow of mice treated with Ra: the role of bystander effects and their potential for therapy. Tombal, B.
Smith, M. Dalla Volta, A. Higher risk of fragility fractures in prostate cancer patients treated with combined radium and abiraterone: prednisone may be the culprit. Sartor, O. Overview of samarium Sm lexidronam in the treatment of painful metastatic bone disease.
Anderson, P. In: Current Advances in Osteosarcoma. Longo, J. Samariumethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases.
Cancer Manag. Chirby, D. Part A Appl. Isotopes 39 , — Eary, J. Goyal, J. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett. Simon, J. Schmidt, M. ImIBG therapy in neuroblastoma: established role and prospective applications. Transl Imaging 4 , 87— Schoot, R. The role of I-metaiodobenzylguanidine MIBG therapy in unresectable and compromising localised neuroblastoma.
Imaging 40 , — George, S. Individualized ImIBG therapy in the management of refractory and relapsed neuroblastoma. Eisenhut, M. Inaki, A. A phase I clinical trial for [ I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma: a study protocol.
Modak, S. Arsenic trioxide as a radiation sensitizer for I-metaiodobenzylguanidine therapy: results of a phase II study. Shilkrut, M. Low-dose iodine metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
Coleman, R. Radiopharm 24 , — Gonias, S. Phase II study of high-dose [ I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
Fitzgerald, P. NY Acad. Sisson, J. Treatment of malignant pheochromocytomas with I metaiodobenzylguanidine and chemotherapy. Mundschenk, J. Therapy of malignant pheochromocytoma. Invitation to participate in a randomized multicenter study. Noto, R. Pinto, J. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Heston, W. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase.
Urology 49 Suppl. Murphy, D. Where to next for theranostics in prostate cancer? Tateishi, U. Novakova, Z. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities. FEBS J. Barinka, C. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.
Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Kozikowski, A. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Early report on small-molecule PSMA inhibitors. Zhou, J. NAAG peptidase inhibitors and their potential for diagnosis and therapy.
Drug Discov. Wu, L. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Liu, T. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry 47 , — Choy, C. Lulabeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice.
Theranostics 7 , — Hofman, M. Efficacy and toxicity of anti-PSMA therapy in prostate cancer using lutetium Derlin, T. Rahbar, K. Muzio, V. Imaging 46 Suppl. Nedrow-Byers, J. Prostate 72 , — Gourni, E. Metal-based PSMA radioligands. Molecules 22 , Wester, H. PSMA-targeted radiopharmaceuticals for imaging and therapy. Ross, J. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines.
Physiologic and Clinical Implications. Cancer 73 , — Cheung, A. Targeting folate receptor alpha for cancer treatment. Kettenbach, K. Comparison study of two differently clicked 18 F-folates-lipophilicity plays a key role. Pharmaceuticals 11 , 30 Siwowska, K. Preclinical development of small-molecular-weight folate-based radioconjugates: a pharmacological perspective.
Imaging 59 , — Therapeutic potential of 47 Sc in comparison to Lu and 90 Y: preclinical investigations. Pharmaceutics 11 , Gupta, A. Direct in vitro and in vivo comparison of Tb and Lu using a tumour-targeting folate conjugate. Snyder, F. Alkyl and alkenyl ethers of glycerol in lipids from normal and neoplastic human tissues. Occurrence and nature of O-alkyl and O-alk-I-enyl moieties of glycerol in lipids of Morris transplanted hepatomas and normal rat liver.
Acta , — Counsell, R. Tumor visualization with a radioiodinated phospholipid ether. Meyer, K. Potential tumor or organ-imaging agents. Radioiodinated phospholipid ethers. Pinchuk, A. Weichert, J. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.
Phosphocholine-based RPT. Baiu, D. Targeted molecular radiotherapy of pediatric solid tumors using a radioiodinated alkyl-phospholipid ether analog. Hall, L. Imaging 7 , — Imaging Biol. Morris, Z. Therapeutic combination of radiolabeled CLR with external beam radiation in head and neck cancer model systems. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Fani, M. Somatostatin receptor antagonists for imaging and therapy.
Trial that demonstrates the greater tumour uptake and absorbed dose with somatostatin receptor antagonists compared with agonists. Strosberg, J.
Phase 3 trial of Ludotatate for midgut neuroendocrine tumors. Kwekkeboom, D. Treatment with the radiolabeled somatostatin analog [ Lu-DOTA 0 ,Tyr 3 ]octreotate: toxicity, efficacy, and survival. Atcher, R. An improved generator for the production of Pb and Bi from Ra Delpassand, E. Stallons, T. Cancer Ther 18 , — Long-term tolerability of PRRT in patients with neuroendocrine tumours: the value and limitations of clinical factors. Imaging 42 , 5—19 Study that demonstrates the toxicity profile of PRRT with 90 Y , Lu or their combination in a large series of patients.
Reidy-Lagunes, D. Phase I trial of well-differentiated neuroendocrine tumors NETs with radiolabeled somatostatin antagonist Lu-satoreotide tetraxetan. Jensen, R. International Union of Pharmacology. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Baratto, L. Prostate cancer theranostics targeting gastrin-releasing peptide receptors.
Pooja, D. Bombesin receptors as potential targets for anticancer drug delivery and imaging. Cell Biol. Morgat, C. Abouzayed, A. Liolios, C. Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells. Imaging the distribution of gastrin releasing peptide receptors in cancer. Med 61 , — LuAMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations.
Imaging 34 , S Cescato, R. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. Dalm, S. Kurth, J. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [ Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Imaging 47 , — Thomas, V. Understanding inter-individual variability in monoclonal antibody disposition. Antibodies 8 , E56 Wohlrab, J. Pharmacokinetic characteristics of therapeutic antibodies.
JDDG 13 , — Kohler, G. Continuous cultures of fused cells secreting antibody of predefined specificity. Nobel Prize-winning work to produce antibodies from a single clone, an essential precursor to antibody-based RPT. Imaging of melanoma with Ilabeled monoclonal antibodies. Among the earliest reports of antibody-based cancer imaging; precursor to antibody-based RPT.
Mach, J. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Colcher, D. Radiolabeled monoclonal-antibody B Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.
Mahe, M. A phase II study of intraperitoneal radioimmunotherapy with iodinelabeled monoclonal antibody OC in patients with residual ovarian carcinoma. Cassaday, R. Phase I study of a CDtargeted antibody-radionuclide conjugate for high-risk lymphoma.
Tomlinson, B. Lymphoma Myeloma Leukemia 19 , S Pagel, J. Allogeneic hematopoietic cell transplantation after conditioning with Ianti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Blood , — Gopal, A. I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Mawad, R. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Blood Marrow Transplant. Griffeth, L. Personalized dosimetry using Ianti-CDapamistamab Iomab-B prior to high-dose myeloablative radioimmunotherapy for hematopoietic stem cell transplant HCT in active, relapsed, or refractory acute myelogenous leukemia: novel re-induction and targeted conditioning feasibility and engraftment results from the SIERRA trial.
Pandit-Taskar, N. Optimizing dosimetry imaging in high-dose radioimmunotherapy using the novel, anti-CD45 re-induction and targeted conditioning agent iodine I apamistamab Iomab-B in patients 55 years or older with active, relapsed or refractory acute myeloid leukemia SIE phase III trial. Schwartz, M. Dose-escalation trial of M labeled with I for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. Allogeneic hematopoietic cell transplantation after conditioning with I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Press, O. Lancet , — Use of RPT for bone marrow ablation in preparation for transplantation. Orozco, J. Anti-CD45 radioimmunotherapy using At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Li, Y. Plos ONE 13 , e Scheinberg, D. A phase I trial of monoclonal antibody M in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-HuM anti-CD33 in patients with leukemia. Preparation of alpha-emitting Bi-labeled antibody constructs for clinical use. Parametric images of antibody pharmacokinetics in BiHuM therapy of leukemia. Rosenblat, T. Sequential cytarabine and alpha-particle immunotherapy with bismuthlintuzumab HuM for acute myeloid leukemia.
Jurcic, J. Targeted alpha-particle therapy for hematologic malignancies. Imaging Radiat. Sci 50 , S53—S57 Phase I trial of the targeted alpha-particle nano-generator actinium Ac -lintuzumab anti-CD33 in combination with low-dose cytarabine LDAC for older patients with untreated acute myeloid leukemia AML.
Berger, M. Actinium labeled daratumumab demonstrates enhanced killing of multiple myeloma cells over naked daratumumab. Dadachova, E. AcCD38 antibody targeting is effective and well tolerated in experimental models of lymphoma and multiple myeloma. Juergens, R. Hagemann, U. Advances in precision oncology: targeted thorium conjugates as a new modality in targeted alpha therapy.
A novel high energy alpha pharmaceutical: in vitro and in vivo potency of a mesothelin-targeted thorium conjugate TTC in a model of bone disease. Mesothelin-targeted thorium conjugate MSLN-TTC : preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers. Hammer, S. AM Grant, D. Imaging 45 , S Karlsson, J. Cancer , E Wickstroem, K. Pharmaceuticals 12 , ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters.
Wahl, R. Iodine anti-B1 antibody for B-cell lymphoma: an update on the Michigan phase I experience. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. Davis, T.
Results of a randomized study of Bexxar TM tositumomab and iodine I tositumomab vs. Blood 98 , A The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I tositumomab. Baxter, L. Transport of fluid and macromolecules in tumors.
A microscopic model of the perivascular distribution. Jain, R. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. Saga, T. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.
Natl Acad. USA 92 , — Fujimori, K. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis [see comments].
Jaggi, J. Improved tumor imaging and therapy via i. IgG-mediated time-sequential modulation of neonatal Fc receptor. Invest , — Goodwin, D. Initial approach to separating radionuclide delivery from cancer targeting to reduce haematological toxicity. Verhoeven, M. Therapeutic applications of pretargeting. Liapi, E. Intra-arterial therapies for hepatocellular carcinoma: where do we stand?
Lewandowski, R. Transcatheter intraarterial therapies: rationale and overview. Radiology , — Yttrium radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Riaz, A. A new set of appropriate use criteria is now available to guide referring and imaging physicians in their use of prostate-specific membrane antigen PSMA PET imaging agents to detect prostate cancer. SNMMI worked collaboratively with four other medical societies to develop criteria for the appropriate use of this new imaging technology.
Members can nominate an early career professional—currently in training or who have completed their training within the last 10 years—whose actions, work, or studies have set them apart as a future thought leader in the field.
Learn More ». Sharpen your skills on radiation safety, instrumentation, clinical procedures, radiopharmacy, and more in this course designed to prepare you for the NMTCB and ARRT examinations. Includes question mock-exam. The new Quality in Nuclear Medicine Online Program is designed to help you understand the skill requirements vital to your quality of practice. We will continuously assess the situation and adapt accordingly. Some governments around the world are providing local guidance that is stricter than this global guidance.
In those cases, the local guidance takes precedence. Given the nature of some of the work undertaken at AAA, it is not possible for everyone to work remotely. By reducing the number of associates visiting our sites, we can protect those employees who cannot work offsite. In addition to the measures above, AAA has updated its general international travel restriction. All international business travel requires approval from an executive level manager, in alignment with local authorities.
Where required, we have enacted mitigation plans to ensure ongoing drug supply to depots for our clinical studies, and we are working closely with the authorities on dispensing to trial participants. As Advanced Accelerators Applications AAA , a Novartis Company, continues to closely monitor the coronavirus situation, our primary concern is the health and safety of our associates and patients globally. We will continue to deliver our medicines to patients around the world and we do not anticipate supply chain disruption at this time.
Radioligand Therapy Discovering and developing nuclear medicine for cancer. Read more. Turning the power of nuclear technology into a medical force.
View Pipeline. Our Products. View Products. Looking For Clinical Trials?
0コメント